Format

Send to

Choose Destination
MAbs. 2009 May-Jun;1(3):247-53.

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.

Author information

1
Department of Pre-Clinical Therapeutics, Seattle Genetics, Inc., Bothell, WA 98021, USA.

Abstract

Reducing the blood supply of tumors is one modality to combat cancer. Monoclonal antibodies are now established as a key therapeutic approach for a range of diseases. Owing to the ability of antibodies to selectively target endothelial cells within the tumor vasculature, vascular targeting programs have become a mainstay in oncology drug development. However, the antitumor activity of single agent administration of conventional anti-angiogenic compounds is limited and the improvements in patient survival are most prominent in combinations with chemotherapy. Furthermore, prolonged treatment with conventional anti-angiogenic drugs is associated with toxicity and drug resistance. These circumstances provide a strong rationale for novel approaches to enhance the efficacy of mAbs targeting tumor vasculature such as antibody-drug conjugates (ADCs).Here, we review trends in the development of ADCs targeting tumor vasculature with the aim of informing future research and development of this class of therapeutics.

PMID:
20069754
PMCID:
PMC2726597
DOI:
10.4161/mabs.1.3.8515
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center